Is PALISADE BIO, INC. (PALI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 4.0% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 4.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.6% / 33% | 90.3% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 4.0% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.6% / 33% | 90.3% / 33% | 0.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -24.5% | |
| Return on Assets (ROA) | -15.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$12M |
| Free Cash Flow | -$12M |
| Total Debt | $169,000 |
| Debt-to-Equity | 0.1 |
| Current Ratio | 29.0 |
| Total Assets | $11M |
Price & Trading
| Last Close | $1.96 |
| 50-Day MA | $1.78 |
| 200-Day MA | $1.45 |
| Avg Volume | 4.4M |
| Beta | 1.6 |
|
52-Week Range
$0.53
| |
About PALISADE BIO, INC. (PALI)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PALISADE BIO, INC. (PALI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PALISADE BIO, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PALISADE BIO, INC.'s debt ratio?
PALISADE BIO, INC.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are PALISADE BIO, INC.'s key financial metrics?
PALISADE BIO, INC. has a market capitalization of $332M. Return on equity stands at -24.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.